P2, N=20, Not yet recruiting, Wayne State University | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Oct 2026 --> Oct 2027

P=N/A, N=35, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Trial completion date: Feb 2028 --> Dec 2028 | Initiation date: Feb 2024 --> Sep 2024 | Trial primary completion date: Feb 2028 --> Dec 2028

P2/3, N=300, Recruiting, Fayoum University | Not yet recruiting --> Recruiting | Initiation date: Aug 2024 --> Dec 2024

P3, N=10, Active, not recruiting, The Hospital for Sick Children | Recruiting --> Active, not recruiting | N=22 --> 10 | Trial completion date: Jun 2024 --> Mar 2025

P=N/A, N=150, Terminated, UMC Utrecht | Unknown status --> Terminated; It was decided to conclude recruitment due to declining eligibility/recruitment rates and an unrealistically long time span to reach full recruitment.

P2, N=28, Not yet recruiting, Rutgers, The State University of New Jersey

P=N/A, N=187, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Nov 2024 | Trial primary completion date: Apr 2025 --> Nov 2024

P3, N=837, Active, not recruiting, Chiesi Farmaceutici S.p.A. | Recruiting --> Active, not recruiting

P3, N=471, Completed, National Institute of Allergy and Infectious Diseases (NIAID)

P2, N=24, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Dec 2027

P3, N=373, Completed, AstraZeneca | Active, not recruiting --> Completed

P3, N=45, Recruiting, Sohag University

P1, N=40, Recruiting, Medical University of South Carolina | Not yet recruiting --> Recruiting

P3, N=117, Terminated, Oculis | Trial completion date: Dec 2024 --> May 2024 | Recruiting --> Terminated; Sponsor decision to close study due to third-party administrative error preventing analysis of trial results. There was no issue in terms of quality of the investigational product, and no safety risk to any study subject.

Combinatorial drug-drug interaction experiments demonstrated that dexamethasone antagonizes the potency of paclitaxel, a chemotherapy agent frequently used in the treatment of AGCT. Thus, gain-of-function pioneering activity contributes to the oncogenic mechanism of FOXL2-C134W and creates a potentially targetable synergy with glucocorticoid signaling.

P=N/A, N=17, Completed, Spectrum Health - Lakeland | Unknown status --> Completed | N=60 --> 17

P1, N=105, Not yet recruiting, AstraZeneca

P3, N=348, Not yet recruiting, Assistance Publique - Hôpitaux de Paris

P4, N=60, Recruiting, Poznan University of Medical Sciences | Not yet recruiting --> Recruiting

P=N/A, N=103117, Completed, NICHD Global Network for Women's and Children's Health | Phase classification: P3 --> P=N/A | N=6214 --> 103117

Additionally, ANXA1 displayed strong binding energy with amcinonide, and MICB with ribavirin. This study identified oxidative stress-related biomarkers (ANXA1, CD36, MICB, and PRDX6) in ULM through transcriptomic and MR analysis, providing valuable insights for ULM therapeutic research.

P4, N=150, Not yet recruiting, AstraZeneca | Trial completion date: Oct 2025 --> Dec 2026 | Initiation date: Sep 2024 --> May 2025 | Trial primary completion date: Oct 2025 --> Oct 2026

P2/3, N=114, Enrolling by invitation, Medical University of Warsaw

Laboratory investigations confirmed hypercortisolism with elevated cortisol and Adrenocorticotropic Hormone(ACTH), with non-suppression on dexamethasone suppression tests...The patient was diagnosed with ectopic Cushing's syndrome secondary to MTC and underwent bilateral adrenalectomy followed by total thyroidectomy. Postoperatively, ACTH levels normalised; however, residual tumour was detected, necessitating external beam radiotherapy.

P4, N=100, Recruiting, Northwestern University | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Oct 2025

P=N/A, N=62, Recruiting, CHU de Reims | Not yet recruiting --> Recruiting | Trial completion date: Mar 2025 --> Mar 2027 | Trial primary completion date: Nov 2024 --> Jan 2027

P4, N=339, Not yet recruiting, Mayo Clinic

Additionally, liposomal DEX can induce the expression of anti-inflammatory cytokines like interleukin-10 (IL-10), which has significant anti-inflammatory and immunoregulatory properties. The findings suggest that liposomal DEX represents a promising candidate for effective and safe RA therapy, with the potential to improve the management of this debilitating disease by providing targeted delivery and sustained release of the drug.

P=N/A, N=50, Recruiting, B.P. Koirala Institute of Health Sciences

P4, N=80, Recruiting, Santhera Pharmaceuticals

Primary human hepatocytes (PHH) were treated with combinations of tumor necrosis factor alpha (TNFα), lipopolysaccharide (LPS), and dexamethasone (DEX) for 24 h, following which chemokine mRNA and protein expression were analyzed using qPCR and enzyme-linked immunosorbent assay assays...GR down-regulated CXCL1 and CXCL8 in different cell types, whereas the specific activation of CXCL2 in hepatocytes and down-regulation of CXCL2 in nonhepatocytes by GR appears due to cell-specific utilization of CXCL2 promoter. By specifically increasing GR activity in the liver, we may normalize chemokine imbalances and prevent sepsis in inflammatory liver diseases.

This study revealed that the incidence of complications in the observation group was 16.00%, which was significantly lower than the 37.50% in the reference group (p < 0.05). Conclusion In the short-term clinical treatment, the combination application of pulmicort respules and azithromycin can effectively improve the immune function of children with recurrent respiratory tract infection caused by MP and relieve their clinical symptoms.

P1/2, N=90, Recruiting, Assiut University | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Dec 2024

P=N/A, N=24, Completed, Hospital for Special Surgery, New York | Enrolling by invitation --> Completed

P=N/A, N=2000, Not yet recruiting, AstraZeneca

P4, N=180, Not yet recruiting, University of Auckland

P4, N=112, Not yet recruiting, prof. Tomas Reischig, MD, PhD - Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital

The C/C genotype of rs1231760 in RGS2 could be a biomarker of high-risk H. pylori-positive AG because of an increase in RGS2 expression.

P1/2, N=68, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Sep 2024 --> Dec 2024

P=N/A, N=5, Terminated, Amsterdam UMC, location VUmc | N=20 --> 5 | Recruiting --> Terminated | Trial primary completion date: Nov 2023 --> Nov 2024; To few participants

P=N/A, N=52, Completed, LifeBridge Health

This study aims to establish a rat model of osteoporosis induced by dexamethasone (DEX) and clarify the alleviating effect of soymilk fermented with Lacticaseibacillus paracasei JM053 on osteoporosis...Fermented soymilk with Lacticaseibacillus paracasei JM053 can alleviate bone metabolism disorders by regulating gut microbiota and metabolite content. This study provides theoretical and data-based support for developing functional products that can alleviate osteoporosis.